Pharmafile Logo

dual tasking

- PMLiVE

Amgen and Plexium announce new research collaboration worth over $500m

The two companies will work to identify and develop new treatments for cancer and other serious diseases

- PMLiVE

MHRA issues CMA for Novavax COVID-19 vaccine

Nuvaxovid offers up to 89% protection against COVID-19

- PMLiVE

EIT Health raises awareness on World Cancer Day 2022

This year’s World Cancer Day raises awareness of global inequities affecting access to care

- PMLiVE

Sanofi unveils new corporate brand and logo

Sanofi Pasteur and Sanofi Genzyme will unite under the new brand image

Were patients at the heart of your New Year’s Resolutions?

Over recent years, many pharma companies have increasingly stated that they have patients at the heart of their success objectives... but if they were to look back and decide whether...

Origins – The Patient Focused Specialists

- PMLiVE

We Need To Talk About We Don’t Talk About Bruno

Tim explores how if we only fixate on giving people what they like, we’ll miss the chance to give them what they don’t know they love yet.

The Good Ideas Group

VR/AR Applications for Training and Healthcare

Mike Waldron, CEO and Co-Founder of Propel VR, discusses how virtual reality (VR) and augmented reality (AR) can be leveraged in the healthcare industry, including specific applications of VR/AR for...

Impetus Digital

Forging Innovative Solutions by Merging Art and Science

Ariel Garten, Founder & Chief Evangelism Officer at Muse, explores many exciting topics such as the idea of whether art and beauty can be broken down into biological codes, the...

Impetus Digital

- PMLiVE

NICE recommends AZ’s Forxiga for kidney disease

The recommendation is based on results from a phase 3 trial

- PMLiVE

Parkinson’s UK and Domainex announce new collaboration

Parkinson’s Virtual Biotech plans to invest up to £3m in the project

- PMLiVE

FDA issues approval for Janssen’s HIV drug Cabenuva

The injectable treatment for adults with HIV can be administered every two months

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links